Home » SYNTONIX, BOEHRINGER DEAL COULD BE WORTH $63 MILLION
SYNTONIX, BOEHRINGER DEAL COULD BE WORTH $63 MILLION
Syntonix Pharmaceuticals Inc., based in Waltham, and German company Boehringer Ingelheim have entered into a collaboration to optimize certain Boehringer Ingelheim therapeutic peptides for inhalation, using Syntonix's SynFusion and Transceptor technologies. Syntonix will receive an upfront fee and research support of up to $63 million.
Mass High Tech (http://www.masshightech.com/displayarticledetail.asp?Art_ID=70044)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May